Oxidants, transcription factors, and intestinal inflammation

Journal of Clinical Gastroenterology

Volumn 25, Issue SUPPL. 1, 1997, Pages

  Jourd'heuil, David ^a   Morise, Zenichi ^a   Conner, Elaine M ^a   Grisham, Matthew B ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Activator protein 1; B cell lymphoma leukemia 2; Nitric oxide; Nuclear transcription factor B; Reactive oxygen metabolites

Indexed keywords

CYTOKINE; FREE RADICAL; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; OXIDIZING AGENT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; CONFERENCE PAPER; CROHN DISEASE; ENTERITIS; GENE EXPRESSION REGULATION; HUMAN; INTESTINE EPITHELIUM CELL; NONHUMAN; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; PROTO ONCOGENE; ULCERATIVE COLITIS;

ANIMALS; APOPTOSIS; FREE RADICALS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTOR AP-1;

EID: 0031423504     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199700001-00011     Document Type: Conference Paper

References (117)

1. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994;344:859-61.
2. Conner EM, Brand SJ, Davis JM, Kang DY, Grisham MB. Role of reactive metabolites of oxygen and nitrogen in lymphocyte bowel disease: toxins, mediators, and modulators of gene expression. Inflam Bowel Dis 1996;2:133-47.
3. Heike L, Baeuerle PA. Oxygen and the control of gene expression. BioEssays 1994;16:497-502.
4. Klebanoff SJ. In: Gallin JI, Goldstein IM, Snyderman R, eds. Oxygen metabolites from phagocytes. Inflammation - basic principles and clinical correlates. New York: Raven Press, 1992:541-58.
5. Buettner GR. The pecking order of free radicals and anti-oxidants: lipid peroxidation, α-tocopherol, and ascorbate. Arch Biochem Biophys 1993;300:535-43.
6. Aikens J, Dix TA. Perhydroxyl radical initiated lipid peroxidation. The role of fatty acid hydroperoxides. J Biol Chem 1991;266:15091-8.
7. Pryor WA. Oxy-radicals and related species: their formation, lifetimes, and reactions. Annu Rev Physiol 1986;48:657-67.
8. Britigan BE, Rosen GM, Thompson BY, Chai Y, Cohen MS. Stimulated human neutrophils limit iron-catalyzed hydroxyl radical formation as detected by spin-trapping techniques. J Biol Chem 1986;261:17026-32.
9. Winterbourn CC, Monteiro HP, Galilee CF. Ferritin-dependent lipid peroxidation by stimulated neutrophils: inhibition by myeloperoxidase-derived hypochlorous acid but not by endogenous lactoferrin. Biochhn Biophys Acta 1990; 1055:179-85.
10. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620.
11. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991;266:4244.
12. Rubbo H, Radi R, Trujillo M, et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation: formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 1994;269:26066.
13. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991;288:481.
14. King PA, Jamison E, Strahs D, Anderson VE, Brenowitz M. 'Footprinting' proteins on DNA with peroxonitrous acid. Nucleic Acids Res 1993;21:2473.
15. Zhu L, Gunn C, Beckman JS. Bactericidal activity of peroxynitrite. Arch Biochem Biophys 1992;298:452.
16. Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992;298:446-51.
17. Miles AM, Bohle DS, Glassbrenner PA, Hansert B, Wink DA, Grisham MB. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 1996;271;40-7.
18. Miller MJS, Sadowska-Krowicka H, Chotinaruemol S, Kakkis JL, Clark DA. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 1993;264: 11-6.
19. Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993;341:465-6.
20. Yamada T, Sartor RB, Marshall S, Specian RD, Grisham MB. Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterology 1993;104: 759-71.
21. Boughton-Smith NK, Evans SM, Hawkey CJ, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993;342:338-40.
22. Grisham MB, Specian RD, Zimmerman TE. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther 1994;271:1114.
23. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002.
24. Pollock JS, Fostermann U, Tracey WR, Nakane M. Nitric oxide synthase isozymes antibodies. Histol J 1995;27:738.
25. Miles AM, Owens MW, Milligan S, et al. Nitric oxide synthase in circulating vs. extravasated polymorphonuclear leukocytes. J Leukocyte Biol 1995;58:616.
26. Weinberg JB, Misukonis MA, Shami PJ, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritonial macrophages. Blood 1995;86:1184.
27. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxide-by bound dioxygen in hemoproteins. J Inorgan Blochem 1981; 14:351-8.
28. Stamler J. Redox signalling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931-6.
29. Kim Y, Bergonia HA, Muller C, Pitt BR, Watkins WD, Lancaster JRJ. Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis. J Biol Chem 1995; 270:5710.
30. Gaginella TS, Kachur JF, Tamai H, Keshavarzian A. Reactive oxygen and nitrogen metabolites as mediators of secretory diarrhea. Gastroenterology 1995;109:2019.
31. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365.
32. Winterbourn CC, van den Berg JJM, Roitman E, Kuypers FA. Chlorohydrin formation from unsaturated fatty acids reacted with hypochlorous acid. Arch Biochem Biophys 1992;296:547.
33. Thomas ED, Grisham MB. Cytotoxicity of chloramines. Methods Enzymol 1986;132:585-93.
34. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci 1998; 33:6s-15s.
35. Keshavarzian A, Sedghi S, Kanofsky J, et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1992;103:177-85.
36. Simmonds NJ, Allen RE, Stevens TRJ, et al. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992;103:186-96.
37. Oshitani N, Kitano A, Okabe H, Nakamura S, Matumoto T, Kobayashi K. Location of superoxide anion generation in human colonic mucosa obtained by biopsy. Gut 1993;34: 936-8.
38. Ahnfelt-Ronne I, Neilson OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990;98:1162-9.
39. McKenzi SJ, Buffinton GD, Baker MS, Doe WF. Colonic epithelial cell glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a target of oxidative injury in inflammatory bowel disease (IBD) [Abstract]. Gastroenterology 1993;104: A741.
40. Aiko S, Grisham MB. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology 1995;109:142-50.
41. Sartor RB. Cytokines in intestinal inflammation. Pathophysiologic and clinical considerations. Gastroenterology 1994;106:533-7.
42. Grisham MB, MacDermott RP, Deitch EA. Oxidant defense mechanisms in the human colon. Inflammation 1990;14:669.
43. Mulder TPJ, Verspaget HW, Janssens AR, de Bruin PAF, Pena AS, Lamers CBHW. Decrease in two intestinal copper/ zinc containing proteins with antioxidant function in inflammatory bowel disease. Gut 1991;32:1146.
44. Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Rad Biol Med 1995;19:911.
45. Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut 1990;31:786.
46. 4 decrease experimental colitis. Dig Dis Sci 1992;37:1866.
47. Blumerstein BJ, Ma CK, Zhang X, Hadzijahic N, Fogel R. Orally administered oxygen radical scavenger (vitamin E) reduces mucosal damage in a rat model of inflammatory colitis [Abstract]. Gastroenterology 1994;105:A2011.
48. Emerit J, Pelletier S, Tosoni-Verilignue D, Mollete M. Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease. Free Rad Biol Med 1989;7:145.
49. Grisham MB, Granger DN. 5-aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine. Dig Dis Sci 1989;34:573.
50. Yamada T, Volkmer C, Grisham MB. Antioxidant properties of 5-ASA: potential mechanism for its antiinflammatory activity. Can J Gastroenterol 1990;4:295-302.
51. Lundberg JON, Hellstrom PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 1994;344:1673-4.
52. Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol 1995;268:G673.
53. Aiko S, Benoit JN, Davis JM, Grisham MB. Effect of acute and chronic NOS inhibition on splanchnic organ blood flow: implications in gut and liver pathophysiology [Abstract]. Gastroenterology 1995;108:A268.
54. - secretion by reactive oxygen metabolites in human colonic T84 cells. J Clin Invest 1991;89:301-7.
55. Tamai H, Kachur JF, Baron DA, Grisham MB, Gaginella TS. Monochloramine, a neutrophil-derived oxidant, stimulates rat colonic secretion. J Pharmacol Exp Ther 1991;257: 887.
56. Grisham MB, Gaginella TS, von Ritter C, Tamai H, Be RM, Granger DN. Effects of neutrophil-derived oxidants on intestinal permeability. Electrolyte transport and cell viability. Inflammation 1990;14:531-42.
57. Baeuerle PA, Henkle T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-79.
58. Kopp E, Ghosh S. NF-κB and Rel proteins in an innate immunity. Adv Immunol 1994;58:1-27.
59. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1995;268:522-3.
60. Lieberman TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol Cell Biol 1990;10:2327-34.
61. Neish AS, Read MA, Thanos D, Pine R, Maniatis T, Collins T. Endothelial IRF-1 cooperates with NF-κB as a transcriptional activator of vascular cell adhesion molecule-1. Mol Cell Biol 1995;19:2558-69.
62. Adcock IM, Brown CR, Kwon O, Barnes PJ. Oxidative stress induced NF-κB binding and inducible NOS mRNA in human epithelial cells. Biochem Biophys Res Commun 1994; 199:1518-24.
63. Shibanuma M, Kuroki T, Nose K. Inhibition by N-acetyl-L-cysteine of interleukin-6 mRNA induction and activation of NF-κB by tumor necrosis factor α in a mouse fibroblastic cell line, Balb/3T3. FEBS Lett 1994;353:62-6.
64. Suzuki YJ, Packer L. Inhibition of NF-κB by vitamin E derivatives. Biochem Biophys Res Commun 1993;193:277-83.
65. Suzuki YJ, Aggarwal BB, Packer L. α-lipoic acid as a potent inhibitors of NF-κB activation in human T cells. Biochem Biophys Res Commun 1992;189:1709-15.
66. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitor of nuclear factor κB in intact cells. J Exp Med 1992;175:11810.
67. Osborn L, Kunkel S, Nabel GJ. TNF-α and interleukin-1 stimulate the human immunodeficiency virus enhancer by activation of the NF-κB. Proc Natl Acad Sci USA 1989;86: 2336-40.
68. Suzuki YJ, Mizuno M, Packer L. Signal transduction for nuclear factor-kB activation. Proposed location of antioxidant-inhibitable step. J Immunol 1994;153:5008-15.
69. Schreck R, Albermann K, Baeuerle PA. NF-κB: an oxidative stress responsive transcription factor of eukaryotic cells. Free Rad Res Commun 1992;17:221-37.
70. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothlial cells. J Clin Invest 1993;95:1262-70.
71. Anderson MT, Staal FJT, Gilter C, Herzenberg LA, Herzenberg LA. Separation of oxidant-initiated and redox-regulated steps in the NF-κB signal transduction pathway. Proc Natl Acad Sci USA 1994;91:11527-31.
72. Barchowsky A, Munro SR, Morona SJ, Vinceti MP, Treadwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-κB and AP-1 in endothelial cells. Am J Physiol 1995;269:L829-36.
73. Veillette A, Dumont S, Fournel M. Conserved cysteine residues are critical for the enzymatic function of the lymphocyte-specific tyrosine protein kinase p56lck. J Biol Chem 1993;268:17547-53.
74. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquination-dependent protein kinase activity. Cell 1996;84:853-62.
75. Toledano MN, Leonard WJ. Modulation of transcription factor NF-κB binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 1991;88:4328-32.
76. Droge W, Schulze-Osthoff K, Mihn S. Functions of glutathione disulfide in immunology and immunopathology. FASEB J 1994;8:1131-8.
77. Peng H-B, Libby L, Lia JK. Induction and stabilization of IkBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem 1995;270:14214-9.
78. Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science 1995;268:522-3.
79. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21.
80. Beg AA, Finco TS, Nanternet PV, Baldwin AS. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I-κB. Mol Cell Biol 1993;13:3301-10.
81. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκB-α proteolysis by site-specific, signal induced phosphorylation. Science 1995;267:1485-8.
82. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κBI precursor protein and the activation of NF-κB. Cell 1994;78:773-85.
83. Shakhov AN, Collart MA, Vassilli P, Nedospasov SA, Jongeneel CV. κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of tumor necrosis factor α gene in primary macrophages. J Exp Med 1990; 171:35-47.
84. Hoyos B, Ballard DW, Bohnlein E, Siekevity M, Greene WC. Kappa-B specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science 1989;244:457-60.
85. Chen CC, Manning AM. Transcriptional regulation of endothelial cell adhesion molecules: a dominant role for NF-κB. Agents Actions 1995;47(suppl.):135-41.
86. Connor EM, Brand S, Grisham MB. Inhibition of chronic granulomatous colitis by a selective proteasome inhibitor: antagonist of nuclear transcription factor kB (NFkB) activation [Abstract]. Gastroenterology 1996;110:A886.
87. Thanos D, Maniatis T. NF-κB. A lesson in family values. Cell 1995;80:529-32.
88. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transcription. Biochim Biophys Acta 1991;1072:129-57.
89. Nakabeppu Y, Ryder K, Nathans D. DNA binding activities of 3 murine Jun proteins: stimulation by Fos. Cell 1988;55: 907-15.
90. 2 and antioxidants have opposite effects on activation of NFκB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J 1993;12:2005-15.
91. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. J Biol Chem 1996;271: 13422-9.
92. Rivka O, Dwarki VJ, Rashid D, Verma IM. Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter. Nature 1990; 348:80-2.
93. Boyle WJ, Smeal T, Defize LHK. Activation of protein kinase C decreases phosphorylation of c-jun at sites that negatively regulate its DNA-binding activity. Cell 1991;64:573-84.
94. Devary Y, Gottlieb RA, Smeal T, Karin M. The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 1992;71:1061-91.
95. Abate C, Patel L, Rausher III FJ, Curran T. Redox regulation of Fos and Jun DNA-binding activity in vitro. Science 1996;249:1157-61.
96. Xanthoudakis S, Miao G, Wang F, Pan YE, Curran T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J 1992;11:3323-35.
97. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994;107:3569-77.
98. Reed JC. Bcl-2 and the regulation of programmed cell death. J Biol Chem 1994;124:1-6.
99. Korsmeyer SJ, Yin X-M, Oltvai ZN, Veis-Novak DJ, Linette GP. Reactive oxygen speices and the regulation of cell death by the Bcl-2 gene family. Biochim Biophys Acta 1995;1271: 63-6.
100. Hockenery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
101. Kane DJ, Sarafian TA, Anton R. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993;262:1274-7.
102. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
103. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-88.
104. Steinman HM. The Bcl-2 oncoprotein functions as a prooxidant. J Biol Chem 1995;270:3487-90.
105. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994;145:1323-36.
106. Merrit AJ, Potten CS, Watson AJM, Loh DY, Nakayama K, Hicman JA. Differential expression of Bcl-2 in intestinal epithelia. Correlation with attenuation of apoptosis in colonic crypt cells and the incidence of colonic neoplasia. J Cell Sci 1995;1081:2261-71.
107. Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996;110:1238-43.
108. Thompson C. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
109. Bedi A, Pasricha PJ, Akhtar AJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55: 1811-6.
110. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995;146:20-6.
111. LeBrun DP, Kamel OW, Cleary ML, Dorfman RF, Warnke RA. Follicular lymphomas of the gastrointestinal tract: pathological features in 31 cases and Bcl-2 oncogenic protein expression. Am J Pathol 1992;140:1327-35.
112. Miyashita T, Harigai M, Krajewska M. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
113. Collins RH Jr, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. N Engl J Med 1983;316:1654-5.
114. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990; 76:655-63.
115. Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease. Ann NY Acad Sci 1992;664: 103-15.
116. Grisham MB, Ware K, Yamada T. Neutrophil-mediated nitrosamine formation: role of nitric exide in rats. Gastroenterology 1992;103:1260-6.
117. Reinshagen M, Rohm H, Geerling I, Eysselein VE, Adler G. Expression of the apoptosis genes Bcl-2 and Bax during the time course of experimental colitis in the rat [Abstract]. Gastroenterology 1996;110:A1111.